Cann Group Ltd - Asset Resilience Ratio
Cann Group Ltd (CAN) has an Asset Resilience Ratio of 1.72% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Cann Group Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Cann Group Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Cann Group Ltd.
Liquid Assets Composition Over Time
This chart breaks down Cann Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Cann Group Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$955.00K | 1.72% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$955.00K | 1.72% |
Asset Resilience Insights
- Limited Liquidity: Cann Group Ltd maintains only 1.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cann Group Ltd Industry Peers by Asset Resilience Ratio
Compare Cann Group Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Cann Group Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Cann Group Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.01% | AU$10.00K ≈ $7.08K |
AU$78.79 Million ≈ $55.75 Million |
-1.76pp |
| 2024-06-30 | 1.77% | AU$1.64 Million ≈ $1.16 Million |
AU$92.77 Million ≈ $65.64 Million |
+1.18pp |
| 2023-06-30 | 0.59% | AU$765.00K ≈ $541.29K |
AU$129.47 Million ≈ $91.61 Million |
-0.78pp |
| 2022-06-30 | 1.37% | AU$1.91 Million ≈ $1.35 Million |
AU$139.66 Million ≈ $98.82 Million |
-1.60pp |
| 2021-06-30 | 2.97% | AU$3.02 Million ≈ $2.14 Million |
AU$101.79 Million ≈ $72.02 Million |
+1.04pp |
| 2020-06-30 | 1.92% | AU$1.47 Million ≈ $1.04 Million |
AU$76.40 Million ≈ $54.06 Million |
-54.57pp |
| 2019-06-30 | 56.49% | AU$46.39 Million ≈ $32.82 Million |
AU$82.11 Million ≈ $58.10 Million |
-35.27pp |
| 2018-06-30 | 91.76% | AU$79.65 Million ≈ $56.36 Million |
AU$86.80 Million ≈ $61.42 Million |
+18.03pp |
| 2017-06-30 | 73.73% | AU$11.11 Million ≈ $7.86 Million |
AU$15.07 Million ≈ $10.67 Million |
-- |
| 2016-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$15.89 Million ≈ $11.25 Million |
-- |
About Cann Group Ltd
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.